Rahul Singhvi, Resilience CEO

Bridge­Bio part­ners with bio­man­u­fac­tur­er Re­silience to pro­duce ear­ly-stage AAV gene ther­a­pies

Bridge­Bio has tapped bio­man­u­fac­tur­ing com­pa­ny Na­tion­al Re­silience to pro­duce two of its ear­ly-phase ade­no-as­so­ci­at­ed virus (AAV) gene ther­a­pies in a part­ner­ship de­signed to run be­yond clin­i­cal tri­als.

Re­silience is tasked to man­u­fac­ture AAV5 gene ther­a­py BBP-631 for con­gen­i­tal adren­al hy­per­pla­sia and AAV9 gene ther­a­py BBP-812 for Cana­van dis­ease. BBP-631 is in a 25-pa­tient Phase I/II tri­al, with ear­ly da­ta ex­pect­ed be­fore the end of the year. Mean­while, BBP-812 is in an 18-pa­tient Phase I/II study, with re­sults like­ly to be un­veiled next year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.